| Name | 2-[1-[(4-tert-butylphenyl)methyl]-5-(3-methylphenyl)indol-3-yl]-2-oxoacetic acid |
|---|---|
| Synonyms |
2-{1-[(4-tert-butylphenyl)methyl]-5-(3-methylphenyl)-1H-indol-3-yl}-2-oxoacetic acid
Allasinin (1-(4-(1,1-Dimethylethyl)benzyl)-5-(3-methylphenyl)-1H-indol-3-yl)oxoacetic acid 2-(1-(4-(tert-butyl)benzyl)-5-(m-tolyl)-1H-indol-3-yl)-2-oxoaceticacid Plasminogen activator inhibitor-1,PAI-1,Serpin family,Abeta,inhibit,Inhibitor,Amyloid-β,Alzheimer's disease,BBB-penetrated,β-amyloid ptide,orally active,Allasinin,memory deficiency 1H-Indole-3-acetic acid, 1-[[4-(1,1-dimethylethyl)phenyl]methyl]-5-(3-methylphenyl)-α-oxo UNII-LL56J87F3X Allasinin, 10 mM in DMSO Aleplasinin |
| Description | Aleplasinin is an orally active, potent, BBB-penetrated and selectiveSERPINE1 (PAI-1, Plasminogen activator inhibitor-1) inhibitor. Aleplasinin increases amyloid-β (Aβ) catabolism and ameliorates amyloid-related pathology. Aleplasinin improves memory deficiency. Aleplasinin can be used for Alzheimer's disease research[1][2]. |
|---|---|
| Related Catalog | |
| References |
[1]. Zhao J, Pei G. Evoking plasmin for beta-amyloid clearance. Cell Res. 2008 Aug;18(8):803-4. |
| Molecular Formula | C28H27NO3 |
|---|---|
| Molecular Weight | 425.51900 |
| Exact Mass | 425.19900 |
| PSA | 59.30000 |
| LogP | 6.22980 |
|
~95%
481629-87-2 |
| Literature: Wyeth Patent: US2003/125371 A1, 2003 ; |
| Precursor 1 | |
|---|---|
| DownStream 0 | |